Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SNCA | P37840 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | RAD52 | P43351 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 2/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.34 |
| ▸ | INSR | P06213 | 1/20 | 0.33 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11917741 | 0.93 | SNCA (0.37) | SNCANPC1POLBGAAMAPT | |
| SCHEMBL11965791 | 0.92 | HCRTR1 (0.40) | SNCANPC1POLBGAAMAPT | |
| SCHEMBL15290725 | 0.90 | SNCA (0.34) | SNCANPC1POLBGAAMAPT | |
| SCHEMBL11917744 | 0.86 | SNCA (0.38) | SNCANPC1POLBGAAMAPT | |
| SCHEMBL12889794 | 0.86 | SNCA (0.32) | SNCA | |
| SCHEMBL11920298 | 0.84 | MAPT (0.43) | SNCANPC1POLBGAAMAPT | |
| SCHEMBL13223484 | 0.84 | ADRB2 (0.41) | SNCANPC1POLBGAAMAPT | |
| SCHEMBL14089536 | 0.82 | NPC1 (0.32) | SNCANPC1POLBRAB9A | |
| SCHEMBL11917742 | 0.82 | MAPT (0.38) | SNCANPC1POLBGAAMAPT | |
| SCHEMBL12595096 | 0.82 | MAPT (0.38) | SNCANPC1POLBGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8241852-B2 | Unsymmetrical cyanine dimer compounds and their application | Life Technologies Corporation (US) | 2012-08-14 | — | — | US | disclosed |
| US-8242251-B2 | Unsymmetrical cyanine dimer compounds and their application | Life Technologies Corporation (US) | 2012-08-14 | — | — | US | disclosed |
| US-20110143337-A1 | UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION | Life Technologies Corporation (US) | 2011-06-16 | — | — | US | disclosed |
| US-20110124085-A1 | UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION | Life Technologies Corporation (US) | 2011-05-26 | — | — | US | disclosed |
| US-7888136-B2 | Comprises benzazolium, pyridinium, or quinolinium connected by methine bridge; reporter molecules for detection of RNA in presence of DNA; solid phase synthesis; kits | Life Technologies Corporation (US) | 2011-02-15 | — | — | US | disclosed |
| US-20080199875-A1 | UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION | INVITROGEN CORPORATION (US) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080199875-A1 | UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION | NSUN2, NSUN3, TRDMT1 | SNCA 3350/4885NPC1 4731/4885POLB 522/4885 |
| US-20110124085-A1 | UNSYMMETRICAL CYANINE DIMER COMPOUNDS AND THEIR APPLICATION | NSUN2, NSUN3, TRDMT1 | SNCA 3350/4885NPC1 4731/4885POLB 522/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.